Women & Infants Hospital of RI: drugs
Schedule G of this filing lists 274 drugs, with an amount and a number of claims for each, as filed. Every amount links to its page of the filing.
The schedule's total is printed as “Total Costs of Prescription Drugs Obtained Through 340B Program Claimed for Reimbursement”. The filings describe the amounts in more than one way. Methods says more.
- 274drugs listed
- $55,496,300.74 (Schedule G, printed total, page 17 of the filing PDF)Total as filed
- 268,715 (Schedule G, printed claims total, page 17 of the filing PDF)Claims total as filed
- 45rows show “fewer than 6” for claims. What this means
All 274 drug rows
| Line | Drug | Amount as filed | Claims as filed |
|---|---|---|---|
| 1 | pembrolizumab 100 mg/4 mL IV SOLN00006302602Listed by the FDA as Keytrudapembrolizumab25 mg/mLinjection, solutionMerck Sharp & Dohme LLC | 9,971,689.13 (Schedule G, line 1, page 10 of the filing PDF) | 1,171 |
| 2 | dostarlimab-glxy 500 mg/10 mL INJ00173089803Listed by the FDA as Jemperlidostarlimab50 mg/mLinjectionGlaxoSmithKline LLC | 3,395,439.29 (Schedule G, line 2, page 10 of the filing PDF) | 275 |
| 3 | Enhertu 100 mg SOLR65597040601Listed by the FDA as Enhertufam-trastuzumab deruxtecan-nxki100 mg/5 mLinjection, powder, lyophilized, for solutionDaiichi Sankyo Inc. | 2,933,497.62 (Schedule G, line 3, page 10 of the filing PDF) | 776 |
| 4 | ocrelizumab (Ocrevus) 300 mg in sodium chloride 0.9% 250 mL IVPB50242015001Listed by the FDA as Ocrevusocrelizumab300 mg/10 mLinjectionGenentech, Inc. | 2,288,292.59 (Schedule G, line 4, page 10 of the filing PDF) | 105 |
| 5 | ustekinumab (Stelara) 90 mg/mL injection57894006103Listed by the FDA as Stelaraustekinumab90 mg/mLinjection, solutionJanssen Biotech, Inc. | 1,711,579.88 (Schedule G, line 5, page 10 of the filing PDF) | 103 |
| 6 | daratumumab-hyaluronidase 1,800 mg-30,000 units INJ 15 mL57894050301Listed by the FDA as Darzalex Fasprodaratumumab and hyaluronidase-fihj (human recombinant)1,800 mg/15 mL; 30,000 units/15 mLinjectionJanssen Biotech, Inc. | 1,500,938.66 (Schedule G, line 6, page 10 of the filing PDF) | 89 |
| 7 | Elahere 100 mg/20 mL SOLN72903085301Listed by the FDA as Elaheremirvetuximab soravtansine5 mg/mLinjection, solutionImmunoGen, Inc. | 1,476,838.08 (Schedule G, line 7, page 10 of the filing PDF) | 148 |
| 8 | atezolizumab 1,200 mg/20 mL VIAL50242091701Listed by the FDA as Tecentriqatezolizumab1,200 mg/20 mLinjection, solutionGenentech, Inc. | 1,262,793.31 (Schedule G, line 8, page 10 of the filing PDF) | 85 |
| 9 | Lynparza 150 mg tablet00310067912Listed by the FDA as Lynparzaolaparib150 mgtablet, film coatedAstraZeneca Pharmaceuticals LP | 1,337,354.76 (Schedule G, line 9, page 10 of the filing PDF) | 102 |
| 10 | Entyvio 300 mg SOLR64764030020Listed by the FDA as Entyviovedolizumab300 mg/5 mLinjection, powder, lyophilized, for solutionTakeda Pharmaceuticals America, Inc. | 1,189,387.40 (Schedule G, line 10, page 10 of the filing PDF) | 307 |
| 11 | bevacizumab-awwb (Mvasi) 400 mg/16 mL INJ VIAL55513020701Listed by the FDA as Mvasibevacizumab-awwb400 mg/16 mLinjection, solutionAmgen, Inc | 998,288.39 (Schedule G, line 11, page 10 of the filing PDF) | 926 |
| 12 | canakinumab (Ilaris, PF,) 150 mg/mL Soln00078073461Listed by the FDA as Ilariscanakinumab150 mg/mLinjection, solutionNovartis Pharmaceuticals Corporation | 839,016.71 (Schedule G, line 12, page 10 of the filing PDF) | 20 |
| 13 | tucatinib (Tukysa) 150 mg Tab51144000260Listed by the FDA as Tukysatucatinib150 mgtabletSeagen Inc. | 785,065.86 (Schedule G, line 13, page 10 of the filing PDF) | 50 |
| 14 | Kisqali tab 400dose00078086742Listed by the FDA as Kisqaliribociclib200 mgtablet, film coatedNovartis Pharmaceuticals Corporation | 754,106.71 (Schedule G, line 14, page 10 of the filing PDF) | 96 |
| 15 | durvalumab 500 mg/10 mL INJ00310461150Listed by the FDA as Imfinzidurvalumab500 mg/10 mLinjection, solutionAstraZeneca Pharmaceuticals LP | 724,602.58 (Schedule G, line 15, page 10 of the filing PDF) | 91 |
| 16 | olaparib (Lynparza) 100 mg Tab00310066812Listed by the FDA as Lynparzaolaparib100 mgtablet, film coatedAstraZeneca Pharmaceuticals LP | 663,802.48 (Schedule G, line 16, page 10 of the filing PDF) | 39 |
| 17 | abemaciclib (Verzenio) 150 mg Tab00002533754Listed by the FDA as Verzenioabemaciclib150 mgtabletEli Lilly and Company | 610,804.70 (Schedule G, line 17, page 10 of the filing PDF) | 46 |
| 18 | romosozumab-aqqg Syrg 210 mg55513099802Listed by the FDA as Evenityromosozumab-aqqg105 mg/1.17 mLinjection, solutionAmgen, Inc | 560,808.75 (Schedule G, line 18, page 10 of the filing PDF) | 298 |
| 19 | nivolumab (Opdivo) 240 mg in sodium chloride 0.9% 26 mL IVPB00003373413Listed by the FDA as Opdivonivolumab10 mg/mLinjectionE.R. Squibb & Sons, L.L.C. | 521,618.99 (Schedule G, line 19, page 10 of the filing PDF) | 101 |
| 20 | sacituzumab govitecan (Trodelvy) 620 mg in sodium chloride 0.9% 500 mL IVPB55135013201Listed by the FDA as Trodelvysacituzumab govitecan180 mgpowder, for solutionGilead Sciences, Inc. | 512,121.71 (Schedule G, line 20, page 11 of the filing PDF) | 200 |
| 21 | mepolizumab (Nucala) injection 300 mg00173088101Listed by the FDA as Nucalamepolizumab100 mg/mLinjection, powder, for solutionGlaxoSmithKline LLC | 509,609.60 (Schedule G, line 21, page 11 of the filing PDF) | 192 |
| 22 | Injectafer 750 mg/15 mL SOLN00517065001Listed by the FDA as Injectaferferric carboxymaltose injection50 mg/mLinjection, solutionAmerican Regent, Inc. | 471,480.74 (Schedule G, line 22, page 11 of the filing PDF) | 791 |
| 23 | palbociclib (Ibrance) 125 mg Tab00069068803Listed by the FDA as Ibrancepalbociclib125 mgtablet, film coatedPfizer Laboratories Div Pfizer Inc | 335,711.56 (Schedule G, line 23, page 11 of the filing PDF) | 32 |
| 24 | pertuzumab-trastuzumab-hyaluronidase (Phesgo) 600 mg-600 mg- 20,000 units/10 mL injection 10 mL50242026001Listed by the FDA as Phesgopertuzumab, trastuzumab, and hyaluronidase-zzxf600 mg/10 mL; 600 mg/10 mL; 20,000 units/10 mLinjection, solutionGenentech, Inc. | 402,925.94 (Schedule G, line 24, page 11 of the filing PDF) | 66 |
| 25 | risankizumab-rzaa (Skyrizi) 1,200 mg in sodium chloride 0.9% 250 mL IVPB00074501501Listed by the FDA as Skyrizirisankizumab-rzaa600 mg/10 mLinjectionAbbVie Inc. | 380,756.10 (Schedule G, line 25, page 11 of the filing PDF) | 62 |
| 26 | abemaciclib (Verzenio) 50 mg Tab00002448354Listed by the FDA as Verzenioabemaciclib50 mgtabletEli Lilly and Company | 379,521.96 (Schedule G, line 26, page 11 of the filing PDF) | 43 |
| 27 | niraparib (Zejula) 200 mg Tab00173091213Listed by the FDA as Zejulaniraparib200 mgtablet, film coatedGlaxoSmithKline LLC | 362,511.39 (Schedule G, line 27, page 11 of the filing PDF) | 32 |
| 28 | ado-trastuzumab emtansine (Kadcyla) 240 mg in sodium chloride 0.9% 250 mL IVPB50242008801Listed by the FDA as Kadcylaado-trastuzumab emtansine20 mg/mLinjection, powder, lyophilized, for solutionGenentech, Inc. | 358,671.12 (Schedule G, line 28, page 11 of the filing PDF) | 128 |
| 29 | immune globulin (Privigen) 10% infusion 30 g44206043820Listed by the FDA as Privigenhuman immunoglobulin G20 g/200 mLliquidCSL Behring AG | 358,155.37 (Schedule G, line 29, page 11 of the filing PDF) | 332 |
| 30 | immune globulin (Privigen) 10% infusion 45 g44206043940Listed by the FDA as Privigenhuman immunoglobulin G40 g/400 mLliquidCSL Behring AG | 332,490.59 (Schedule G, line 30, page 11 of the filing PDF) | 160 |
| 31 | Avsola 100 mg SOLR55513067001Listed by the FDA as Avsolainfliximab-axxq100 mg/10 mLinjection, powder, lyophilized, for solutionAmgen, Inc | 328,560.22 (Schedule G, line 31, page 11 of the filing PDF) | 591 |
| 32 | denosumab (Prolia) 60 mg/mL Syrg55513071021Listed by the FDA as Proliadenosumab60 mg/mLinjectionAmgen, Inc | 307,047.42 (Schedule G, line 32, page 11 of the filing PDF) | 369 |
| 33 | niraparib (Zejula) 100 mg Tab00173090913Listed by the FDA as Zejulaniraparib100 mgtablet, film coatedGlaxoSmithKline LLC | 298,259.38 (Schedule G, line 33, page 11 of the filing PDF) | 21 |
| 34 | Kanjinti 150 mg SOLR55513014101Listed by the FDA as Kanjintitrastuzumab-anns150 mg/7.15 mLinjection, powder, lyophilized, for solutionAmgen, Inc | 293,652.87 (Schedule G, line 34, page 11 of the filing PDF) | 1,349 |
| 35 | amivantamab vmjw 350 mg/7 mL INJ57894050101Listed by the FDA as Rybrevantamivantamab-vmjw350 mginjectionJanssen Biotech, Inc. | 270,002.91 (Schedule G, line 35, page 11 of the filing PDF) | 27 |
| 36 | Ibrance 100 mg tablet00069048603Listed by the FDA as Ibrancepalbociclib100 mgtablet, film coatedPfizer Laboratories Div Pfizer Inc | 355,679.40 (Schedule G, line 36, page 11 of the filing PDF) | 32 |
| 37 | risankizumab-rzaa (Skyrizi) 360 mg/2.4 mL (150 mg/mL) Injt00074107001Listed by the FDA as Skyrizirisankizumab-rzaakitAbbVie Inc. | 321,483.52 (Schedule G, line 37, page 11 of the filing PDF) | 21 |
| 38 | onabotulinumtoxinA (Botox) 100 units injection00023114501Listed by the FDA as BotoxonabotulinumtoxinA100 USP unitsinjection, powder, lyophilized, for solutionAllergan, Inc. | 256,478.22 (Schedule G, line 38, page 11 of the filing PDF) | 493 |
| 39 | lenvatinib (Lenvima) 14 mg/day(10 mg x 1-4 mg x 1) cap62856071430Listed by the FDA as LenvimalenvatinibkitEisai Inc. | 252,843.19 (Schedule G, line 39, page 11 of the filing PDF) | 26 |
| 40 | goserelin (Zoladex) injection 3.6 mg70720095036Listed by the FDA as Zoladexgoserelin3.6 mgimplantTerSera Therapeutics LLC | 252,179.93 (Schedule G, line 40, page 11 of the filing PDF) | 272 |
| 41 | riTUXimab-pvvr (Ruxience) 680 mg in sodium chloride 0.9% 680 mL IVPB00069024901Listed by the FDA as Ruxiencerituximab-pvvr500 mg/50 mLinjection, solutionPfizer Laboratories Div Pfizer Inc | 251,511.78 (Schedule G, line 41, page 11 of the filing PDF) | 197 |
| 42 | Bridion 200 mg/2 mL SOLN00006542312Listed by the FDA as Bridionsugammadex100 mg/mLinjection, solutionMerck Sharp & Dohme LLC | 248,920.64 (Schedule G, line 42, page 11 of the filing PDF) | 3,093 |
| 43 | dupilumab (Dupixent Pen) 300 mg/2 mL PnIj00024591502Listed by the FDA as Dupixentdupilumab300 mg/2 mLinjection, solutionSanofi-Aventis U.S. LLC | 239,746.88 (Schedule G, line 43, page 11 of the filing PDF) | 60 |
| 44 | goserelin (Zoladex) injection 10.8 mg70720095130Listed by the FDA as Zoladexgoserelin10.8 mgimplantTerSera Therapeutics LLC | 223,846.26 (Schedule G, line 44, page 11 of the filing PDF) | 115 |
| 45 | ado-trastuzumab emtansine (Kadcyla) 260 mg in sodium chloride 0.9% 250 mL IVPB50242008701Listed by the FDA as Kadcylaado-trastuzumab emtansine20 mg/mLinjection, powder, lyophilized, for solutionGenentech, Inc. | 222,057.72 (Schedule G, line 45, page 11 of the filing PDF) | 45 |
| 46 | tirzepatide (Mounjaro) 5 mg/0.5 mL pen-injector00002149580Listed by the FDA as Mounjarotirzepatide5 mg/0.5 mLinjection, solutionEli Lilly and Company | 196,352.62 (Schedule G, line 46, page 11 of the filing PDF) | 256 |
| 47 | ipilimumab 60 mg in sodium chloride 0.9% 50 mL IVPB00003232711Listed by the FDA as Yervoyipilimumab5 mg/mLinjectionE.R. Squibb & Sons, L.L.C. | 218,515.62 (Schedule G, line 47, page 11 of the filing PDF) | 18 |
| 48 | immune globulin (Gamunex-C) 10% infusion 120 g13533080040Listed by the FDA as Gamunex-Cimmune globulin (human)10 g/100 mLinjectionGrifols USA, LLC | 212,195.96 (Schedule G, line 48, page 11 of the filing PDF) | 78 |
| 49 | adalimumab 40 mg/0.4 mL PnKt00074055402Listed by the FDA as HumiraadalimumabkitAbbVie Inc. | 207,688.22 (Schedule G, line 49, page 11 of the filing PDF) | 77 |
| 50 | abatacept (Orencia) 750 mg in sodium chloride 0.9% 100 mL IVPB00003218713Listed by the FDA as Orenciaabatacept250 mg/15 mLinjection, powder, lyophilized, for solutionE.R. Squibb & Sons, L.L.C. | 204,069.18 (Schedule G, line 50, page 11 of the filing PDF) | 192 |
| 51 | trabectedin (Yondelis) 1.55 mg in sodium chloride 0.9% 500 mL IVPB59676061001Listed by the FDA as Yondelistrabectedin0.05 mg/mLinjection, powder, lyophilized, for solutionJanssen Products, LP | 185,621.32 (Schedule G, line 51, page 11 of the filing PDF) | 80 |
| 52 | bictegravir-emtricitabine-tenofovir (Biktarvy) 50-200-25 mg Tab61958250101Listed by the FDA as Biktarvybictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate50 mg; 200 mg; 25 mgtabletGilead Sciences, Inc. | 225,646.68 (Schedule G, line 52, page 11 of the filing PDF) | 76 |
| 53 | Mounjaro inj 7.5/0.500002148480Listed by the FDA as Mounjarotirzepatide7.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 187,063.10 (Schedule G, line 53, page 11 of the filing PDF) | 238 |
| 54 | immune globulin 20 g/200 mL (10%) IV SOLN (Gammagard)00944270006Listed by the FDA as Gammagard Liquidimmune globulin infusion (human)100 mg/mLinjection, solutionTakeda Pharmaceuticals America, Inc. | 160,118.06 (Schedule G, line 54, page 11 of the filing PDF) | 124 |
| 55 | bevacizumab-awwb (Mvasi) 100 mg/4 mL INJ VIAL55513020601Listed by the FDA as Mvasibevacizumab-awwb100 mg/4 mLinjection, solutionAmgen, Inc | 159,531.39 (Schedule G, line 55, page 11 of the filing PDF) | 792 |
| 56 | immune globulin (Gamunex-C) 10% infusion 20 g13533080024Listed by the FDA as Gamunex-Cimmune globulin (human)10 g/100 mLinjectionGrifols USA, LLC | 158,492.47 (Schedule G, line 56, page 11 of the filing PDF) | 113 |
| 57 | Mounjaro inj 10 mg/0.500002147180Listed by the FDA as Mounjarotirzepatide10 mg/0.5 mLinjection, solutionEli Lilly and Company | 182,382.93 (Schedule G, line 57, page 11 of the filing PDF) | 235 |
| 58 | Inflectra 100 mg SOLR00069080901Listed by the FDA as Inflectrainfliximab-dyyb100 mg/10 mLinjection, powder, lyophilized, for solutionPfizer Laboratories Div Pfizer Inc | 154,814.12 (Schedule G, line 58, page 12 of the filing PDF) | 437 |
| 59 | enfortumab vedotin 20 mg PWDI51144002001Listed by the FDA as Padcev EJFVenfortumab vedotin20 mg/2 mLinjection, powder, lyophilized, for solutionSeagen Inc. | 154,477.52 (Schedule G, line 59, page 12 of the filing PDF) | 20 |
| 60 | PACLitaxeL protein-bound (Abraxane) 125 mg in sodium chloride 0.9% 25 mL IVPB00517430001Listed by the FDA as Paclitaxel Protein Bound Particles Albumin Boundpaclitaxel100 mg/20 mLinjection, powder, lyophilized, for suspensionAmerican Regent, Inc. | 151,223.62 (Schedule G, line 60, page 12 of the filing PDF) | 164 |
| 61 | tezepelumab-ekko (Tezspire) injection 210 mg55513011201Listed by the FDA as Tezspiretezepelumab-ekko210 mg/1.9 mLinjection, solutionAmgen Inc | 150,619.94 (Schedule G, line 61, page 12 of the filing PDF) | 61 |
| 62 | telisotuzumab vedotin tllv 100 mg PWDI00074105501Listed by the FDA as Emrelistelisotuzumab vedotin100 mg/mLinjection, powder, lyophilized, for solutionAbbVie Inc. | 146,837.44 (Schedule G, line 62, page 12 of the filing PDF) | fewer than 6 (the count is not shown) |
| 63 | anifrolumab (Saphnelo) 300 mg in sodium chloride 0.9% 100 mL IVPB00310304000Listed by the FDA as Saphneloanifrolumab-fnia300 mg/2 mLinjection, solutionAstraZeneca Pharmaceuticals LP | 146,326.48 (Schedule G, line 63, page 12 of the filing PDF) | 50 |
| 64 | elotuzumab (Empliciti) 2,400 mg in sodium chloride 0.9% 500 mL IVPB00003452211Listed by the FDA as Emplicitielotuzumab400 mginjection, powder, lyophilized, for solutionE.R. Squibb & Sons, L.L.C. | 145,351.17 (Schedule G, line 64, page 12 of the filing PDF) | 9 |
| 65 | panitumumab (Vectibix) 500 mg in sodium chloride 0.9% 75 mL IVPB55513095601Listed by the FDA as Vectibixpanitumumab400 mg/20 mLsolutionAmgen, Inc | 143,534.50 (Schedule G, line 65, page 12 of the filing PDF) | 21 |
| 66 | tisotumab vedotin (Tivdak) 130 mg in sodium chloride 0.9% 100 mL chemo IVPB51144000301Listed by the FDA as Tivdaktisotumab vedotin40 mg/4 mLinjection, powder, for solutionSeagen Inc. | 137,803.12 (Schedule G, line 66, page 12 of the filing PDF) | 14 |
| 67 | Exparel 1.3% SUSP65250013304Listed by the FDA as Exparelbupivacaine13.3 mg/mLinjection, suspension, liposomalPacira Pharmaceuticals, Inc. | 133,592.70 (Schedule G, line 67, page 12 of the filing PDF) | 18 |
| 68 | Herceptin Hylecta 600-10,000 mg-units/5 mL SOLN50242007701Listed by the FDA as Herceptin Hylectatrastuzumab and hyaluronidase-oysk600 mg/5 mL; 10,000 units/5 mLinjection, solutionGenentech, Inc. | 132,496.44 (Schedule G, line 68, page 12 of the filing PDF) | 119 |
| 69 | Mounjaro inj 15 mg/0.500002145780Listed by the FDA as Mounjarotirzepatide15 mg/0.5 mLinjection, solutionEli Lilly and Company | 146,220.99 (Schedule G, line 69, page 12 of the filing PDF) | 190 |
| 70 | Mirena (52 mg) 20 mcg/DAY IUD50419042301Listed by the FDA as Mirenalevonorgestrel52 mgintrauterine deviceBayer HealthCare Pharmaceuticals Inc. | 124,247.25 (Schedule G, line 70, page 12 of the filing PDF) | 278 |
| 71 | denosumab 120 mg/1.7 mL55513073001Listed by the FDA as Xgevadenosumab120 mg/1.7 mLinjectionAmgen, Inc | 121,494.47 (Schedule G, line 71, page 12 of the filing PDF) | 85 |
| 72 | tirzepatide (Mounjaro) 12.5 mg/0.5 mL pen-injector00002146080Listed by the FDA as Mounjarotirzepatide12.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 131,900.58 (Schedule G, line 72, page 12 of the filing PDF) | 164 |
| 73 | ribociclib (Kisqali) 200 mg/day (200 mg x 1) tablet00078086001Listed by the FDA as Kisqaliribociclib200 mgtablet, film coatedNovartis Pharmaceuticals Corporation | 121,285.56 (Schedule G, line 73, page 12 of the filing PDF) | 33 |
| 74 | omalizumab (Xolair) injection 150 mg50242004062Listed by the FDA as Xolairomalizumab150 mg/1.2 mLinjection, solutionGenentech, Inc. | 115,657.80 (Schedule G, line 74, page 12 of the filing PDF) | 148 |
| 75 | daratumumab 400 mg/20 mL SOLN INJ57894050520Listed by the FDA as Darzalex IVdaratumumab100 mg/5 mLinjection, solution, concentrateJanssen Biotech, Inc. | 114,020.39 (Schedule G, line 75, page 12 of the filing PDF) | 18 |
| 76 | nivolumab (Opdivo) 110 mg in sodium chloride 0.9% 50 mL IVPB00003377211Listed by the FDA as Opdivonivolumab10 mg/mLinjectionE.R. Squibb & Sons, L.L.C. | 113,462.50 (Schedule G, line 76, page 12 of the filing PDF) | 31 |
| 77 | semaglutide (Ozempic) 1 mg/dose (4 mg/3 mL) pen-injector00169413013Listed by the FDA as Ozempicsemaglutide1.34 mg/mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 113,052.90 (Schedule G, line 77, page 12 of the filing PDF) | 176 |
| 78 | luspatercept (Reblozyl) subcutaneous injection 136 mg59572077501Listed by the FDA as Reblozylluspatercept75 mginjection, powder, lyophilized, for solutionCelgene Corporation | 107,304.50 (Schedule G, line 78, page 12 of the filing PDF) | 9 |
| 79 | capivasertib (Truqap) 200 mg Tab00310950101Listed by the FDA as Truqapcapivasertib200 mgtablet, film coatedAstraZeneca Pharmaceuticals LP | 107,000.40 (Schedule G, line 79, page 12 of the filing PDF) | 9 |
| 80 | Entyvio 108 mg/0.68 mL pen64764010821Listed by the FDA as Entyvio Penvedolizumab108 mg/0.68 mLinjection, solutionTakeda Pharmaceuticals America, Inc. | 103,982.66 (Schedule G, line 80, page 12 of the filing PDF) | 26 |
| 81 | ipilimumab 330 mg in sodium chloride 0.9% 250 mL IVPB00003232822Listed by the FDA as Yervoyipilimumab5 mg/mLinjectionE.R. Squibb & Sons, L.L.C. | 102,988.48 (Schedule G, line 81, page 12 of the filing PDF) | fewer than 6 (the count is not shown) |
| 82 | eriBULin (Halaven) 2 mg in sodium chloride 0.9% 100 mL IVPB62856038901Listed by the FDA as Halaveneribulin mesylate0.5 mg/mLinjectionEisai Inc. | 102,011.49 (Schedule G, line 82, page 12 of the filing PDF) | 114 |
| 83 | Cabenuva 600 & 900 mg/3 mL SUER49702024015Listed by the FDA as Cabenuvacabotegravir and rilpivirinekitViiV Healthcare Company | 101,026.41 (Schedule G, line 83, page 12 of the filing PDF) | 26 |
| 84 | capivasertib (Truqap) 160 mg Tab00310950002Listed by the FDA as Truqapcapivasertib160 mgtablet, film coatedAstraZeneca Pharmaceuticals LP | 100,722.44 (Schedule G, line 84, page 12 of the filing PDF) | fewer than 6 (the count is not shown) |
| 85 | pemivibart (Pemgarda) 4,500 mg in sodium chloride 0.9% 50 mL IVPB81960003103Listed by the FDA as Pemgardapemivibart125 mg/mLinjectionInvivyd, Inc | 99,300.00 (Schedule G, line 85, page 12 of the filing PDF) | 13 |
| 86 | inFLIXimab (Remicade) 100 mg/10 mL PWDI57894003001Listed by the FDA as Remicadeinfliximab100 mg/10 mLinjection, powder, lyophilized, for solutionJanssen Biotech, Inc. | 98,881.88 (Schedule G, line 86, page 12 of the filing PDF) | 111 |
| 87 | lenvatinib (Lenvima) 8 mg/day (4 mg x 2) cap62856070830Listed by the FDA as Lenvimalenvatinib4 mgcapsuleEisai Inc. | 95,849.52 (Schedule G, line 87, page 12 of the filing PDF) | 8 |
| 88 | tirzepatide, weight loss, (Zepbound) 10 mg/0.5 mL pen-injector00002247180Listed by the FDA as Zepboundtirzepatide10 mg/0.5 mLinjection, solutionEli Lilly and Company | 95,029.80 (Schedule G, line 88, page 12 of the filing PDF) | 111 |
| 89 | budesonide (Uceris) 9 mg TaDE68682030930Listed by the FDA as Budesonide9 mgtablet, extended releaseOceanside Pharmaceuticals | 94,045.07 (Schedule G, line 89, page 12 of the filing PDF) | fewer than 6 (the count is not shown) |
| 90 | immune globulin (Privigen) 10% infusion 110 g44206043710Listed by the FDA as Privigenhuman immunoglobulin G10 g/100 mLliquidCSL Behring AG | 93,790.56 (Schedule G, line 90, page 12 of the filing PDF) | 170 |
| 91 | ferumoxytol (Feraheme) 1,020 mg in sodium chloride 0.9% 100 mL IVPB59338077501Listed by the FDA as Ferahemeferumoxytol510 mg/17 mLinjectionAMAG Pharmaceuticals, Inc | 90,987.65 (Schedule G, line 91, page 12 of the filing PDF) | 150 |
| 92 | mirikizumab-mrkz 900 mg in sodium chloride 0.9% 250 mL IVPB00002757501Listed by the FDA as Omvohmirikizumab-mrkz20 mg/mLinjection, solutionEli Lilly and Company | 90,231.22 (Schedule G, line 92, page 12 of the filing PDF) | fewer than 6 (the count is not shown) |
| 93 | margetuximab-cmkb 250 mg /10 mL INJ74527002202Listed by the FDA as Margenzamargetuximab-cmkb25 mg/mLinjection, solution, concentrateMacroGenics, Inc | 90,121.35 (Schedule G, line 93, page 12 of the filing PDF) | 6 |
| 94 | tirzepatide, weight loss, (Zepbound) 5 mg/0.5 mL pen-injector00002249580Listed by the FDA as Zepboundtirzepatide5 mg/0.5 mLinjection, solutionEli Lilly and Company | 89,510.35 (Schedule G, line 94, page 12 of the filing PDF) | 112 |
| 95 | Neulasta Onpro 6 mg/0.6 mL SOSY55513019201Listed by the FDA as NeulastapegfilgrastimkitAmgen, Inc | 87,910.14 (Schedule G, line 95, page 12 of the filing PDF) | 16 |
| 96 | donanemab-azbt (Kisunla) 1,400 mg in sodium chloride 0.9% 250 mL00002940101Listed by the FDA as Kisunladonanemab-azbt17.5 mg/mLinjection, solutionEli Lilly and Company | 87,670.19 (Schedule G, line 96, page 13 of the filing PDF) | 54 |
| 97 | lenvatinib (Lenvima) 10 mg/day (10 mg x 1) cap62856071030Listed by the FDA as Lenvimalenvatinib10 mgcapsuleEisai Inc. | 87,634.31 (Schedule G, line 97, page 13 of the filing PDF) | 8 |
| 98 | cetuximab (Erbitux) IVPB 500 mg66733095823Listed by the FDA as Erbituxcetuximab2 mg/mLsolutionImClone LLC | 86,927.09 (Schedule G, line 98, page 13 of the filing PDF) | 28 |
| 99 | Ozempic inj 0.25 mg/0.5 mg 3 mL00169418113Listed by the FDA as Ozempicsemaglutide0.68 mg/mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 85,955.35 (Schedule G, line 99, page 13 of the filing PDF) | 206 |
| 100 | Venofer 20 mg/mL SOLN00517231005Listed by the FDA as Venoferiron sucrose20 mg/mLinjection, solutionAmerican Regent, Inc. | 85,332.54 (Schedule G, line 100, page 13 of the filing PDF) | 704 |
| 101 | Actemra 200 mg/10 mL SOLN50242013601Listed by the FDA as Actemratocilizumab200 mg/10 mLinjection, solution, concentrateGenentech, Inc. | 84,316.79 (Schedule G, line 101, page 13 of the filing PDF) | 62 |
| 102 | nivolumab (Opdivo) 200 mg in sodium chloride 0.9% 50 mL IVPB00003377412Listed by the FDA as Opdivonivolumab10 mg/mLinjectionE.R. Squibb & Sons, L.L.C. | 83,772.82 (Schedule G, line 102, page 13 of the filing PDF) | 40 |
| 103 | Ozempic inj 8 mg/3 mL00169477212Listed by the FDA as Ozempicsemaglutide2.68 mg/mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 83,472.51 (Schedule G, line 103, page 13 of the filing PDF) | 233 |
| 104 | immune globulin (Gammagard) 10% infusion 30 g (Patient Supplied)00944270007Listed by the FDA as Gammagard Liquidimmune globulin infusion (human)100 mg/mLinjection, solutionTakeda Pharmaceuticals America, Inc. | 81,757.38 (Schedule G, line 104, page 13 of the filing PDF) | 34 |
| 105 | tirzepatide, weight loss, (Zepbound) 7.5 mg/0.5 mL pen-injector00002248480Listed by the FDA as Zepboundtirzepatide7.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 81,413.26 (Schedule G, line 105, page 13 of the filing PDF) | 98 |
| 106 | MPB Spevigo 450 mg/7.5 mL SDV 200597003510Listed by the FDA as Spevigospesolimab-sbzo60 mg/mLinjectionBoehringer Ingelheim Pharmaceuticals, Inc. | 80,380.34 (Schedule G, line 106, page 13 of the filing PDF) | fewer than 6 (the count is not shown) |
| 107 | tirzepatide, weight loss, (Zepbound) 12.5 mg/0.5 mL pen-injector00002246080Listed by the FDA as Zepboundtirzepatide12.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 79,481.21 (Schedule G, line 107, page 13 of the filing PDF) | 100 |
| 108 | guselkumab 200 mg/20 mL INJ57894065002Listed by the FDA as Tremfyaguselkumab200 mg/20 mLinjectionJanssen Biotech, Inc. | 79,344.26 (Schedule G, line 108, page 13 of the filing PDF) | 10 |
| 109 | mepolizumab (Nucala) 100 mg/mL AtIn00173089201Listed by the FDA as Nucalamepolizumab100 mg/mLinjection, solutionGlaxoSmithKline LLC | 78,378.83 (Schedule G, line 109, page 13 of the filing PDF) | 17 |
| 110 | aprepitant (Cinvanti) injection 130 mg47426020101Listed by the FDA as Cinvantiaprepitant130 mg/18 mLinjection, emulsionHeron Therapeutics, Inc. | 78,003.32 (Schedule G, line 110, page 13 of the filing PDF) | 561 |
| 111 | niraparib (Zejula) 300 mg Tab00173091513Listed by the FDA as Zejulaniraparib300 mgtablet, film coatedGlaxoSmithKline LLC | 74,619.52 (Schedule G, line 111, page 13 of the filing PDF) | 6 |
| 112 | panitumumab (Vectibix) 300 mg in sodium chloride 0.9% 100 mL IVPB55513095401Listed by the FDA as Vectibixpanitumumab100 mg/5 mLsolutionAmgen, Inc | 72,362.65 (Schedule G, line 112, page 13 of the filing PDF) | 42 |
| 113 | natalizumab (Tysabri) 300 mg in sodium chloride 0.9% 85 mL infusion64406000801Listed by the FDA as Tysabrinatalizumab300 mg/15 mLinjectionBiogen Inc. | 71,169.48 (Schedule G, line 113, page 13 of the filing PDF) | 59 |
| 114 | lurbinectedin 4 mg PWDI68727071201Listed by the FDA as Zepzelcalurbinectedin0.5 mg/mLinjection, powder, lyophilized, for solutionJazz Pharmaceuticals, Inc. | 70,504.34 (Schedule G, line 114, page 13 of the filing PDF) | 15 |
| 115 | irbesartan (Avapro) 300 mg tablet31722073190Listed by the FDA as Irbesartan300 mgtabletCamber Pharmaceuticals, Inc. | 69,987.40 (Schedule G, line 115, page 13 of the filing PDF) | fewer than 6 (the count is not shown) |
| 116 | acalabrutinib maleate (Calquence, acalabrutinib mal,) 100 mg Tab00310351260Listed by the FDA as Calquenceacalabrutinib100 mgtablet, film coatedAstraZeneca Pharmaceuticals LP | 69,810.93 (Schedule G, line 116, page 13 of the filing PDF) | 6 |
| 117 | immune globulin (Gamunex-C) 15 g13533080020Listed by the FDA as Gamunex-Cimmune globulin (human)10 g/100 mLinjectionGrifols USA, LLC | 67,456.76 (Schedule G, line 117, page 13 of the filing PDF) | 204 |
| 118 | glecaprevir-pibrentasvir (Mavyret) 100-40 mg Tab00074262528Listed by the FDA as Mavyretglecaprevir and pibrentasvir40 mg; 100 mgtablet, film coatedAbbVie Inc. | 67,078.28 (Schedule G, line 118, page 13 of the filing PDF) | fewer than 6 (the count is not shown) |
| 119 | romiPLOStim 500 mcg PWDI55513022201Listed by the FDA as Nplateromiplostim500 mcg/mLinjection, powder, lyophilized, for solutionAmgen, Inc | 55,981.98 (Schedule G, line 119, page 13 of the filing PDF) | 30 |
| 120 | tirzepatide (Mounjaro) 2.5 mg/0.5 mL PnIj00002150680Listed by the FDA as Mounjarotirzepatide2.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 81,976.48 (Schedule G, line 120, page 13 of the filing PDF) | 108 |
| 121 | belimumab (Benlysta) 1,080 mg in sodium chloride 0.9% 250 mL IVPB49401010101Listed by the FDA as Benlystabelimumab120 mg/1.5 mLinjection, powder, lyophilized, for solutionGlaxoSmithKline LLC | 66,058.44 (Schedule G, line 121, page 13 of the filing PDF) | 12 |
| 122 | octreotide (SandoSTATIN) injection 30 mg00078082581Listed by the FDA as Sandostatin LAR Depotoctreotide acetatekitNovartis Pharmaceuticals Corporation | 64,895.25 (Schedule G, line 122, page 13 of the filing PDF) | 59 |
| 123 | Zepbound inj 15/0.5 mL00002245780Listed by the FDA as Zepboundtirzepatide15 mg/0.5 mLinjection, solutionEli Lilly and Company | 64,343.34 (Schedule G, line 123, page 13 of the filing PDF) | 86 |
| 124 | teprotumumab trbw 500 mg PWDI75987013015Listed by the FDA as Tepezzateprotumumab500 mginjection, powder, lyophilized, for solutionHorizon Therapeutics USA, Inc. | 63,251.55 (Schedule G, line 124, page 13 of the filing PDF) | 12 |
| 125 | golimumab (Simponi Aria) 110 mg in sodium chloride 0.9% 100 mL IVPB57894035001Listed by the FDA as Simponi Ariagolimumab50 mg/4 mLsolutionJanssen Biotech, Inc. | 61,507.01 (Schedule G, line 125, page 13 of the filing PDF) | 10 |
| 126 | irinotecan liposomal 43 mg/10 mL INJ15054004301Listed by the FDA as Onivydeirinotecan hydrochloride4.3 mg/mLinjection, powder, for solutionIpsen Biopharmaceuticals, Inc. | 60,464.40 (Schedule G, line 126, page 13 of the filing PDF) | 28 |
| 127 | Ofev 150 mg capsule00597014560Listed by the FDA as Ofevnintedanib150 mgcapsuleBoehringer Ingelheim Pharmaceuticals, Inc. | 60,058.96 (Schedule G, line 127, page 13 of the filing PDF) | 55 |
| 128 | semaglutide, weight loss, (Wegovy) 2.4 mg/0.75 mL pen-injector00169452414Listed by the FDA as Wegovysemaglutide2.4 mg/0.75 mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 62,699.92 (Schedule G, line 128, page 13 of the filing PDF) | 97 |
| 129 | risankizumab-rzaa (Skyrizi) 180 mg/1.2 mL (150 mg/mL) Injt00074106501Listed by the FDA as Skyrizirisankizumab-rzaakitAbbVie Inc. | 59,729.60 (Schedule G, line 129, page 13 of the filing PDF) | 6 |
| 130 | telisotuzumab vedotin-tllv (Emrelis) 120 mg in sodium chloride 0.9% 50 mL IVPB00074104401Listed by the FDA as Emrelistelisotuzumab vedotin20 mg/mLinjection, powder, lyophilized, for solutionAbbVie Inc. | 49,698.90 (Schedule G, line 130, page 13 of the filing PDF) | 6 |
| 131 | immune globulin (human) (Octagam) 10% infusion 40 g68982085004Listed by the FDA as Octagam Immune Globulin (Human)immune globulin100 mg/mLsolutionOctapharma USA Inc | 56,995.58 (Schedule G, line 131, page 13 of the filing PDF) | 37 |
| 132 | isatuximab-irfc (Sarclisa) 1,000 mg in sodium chloride 0.9% 250 mL IVPB00024065601Listed by the FDA as Sarclisaisatuximab500 mg/25 mLinjection, solution, concentrateSanofi-Aventis U.S. LLC | 47,115.20 (Schedule G, line 132, page 13 of the filing PDF) | 8 |
| 133 | Trokendi XR 100 mg Cp2417772010330Listed by the FDA as Trokendi XRtopiramate100 mgcapsule, extended releaseSupernus Pharmaceuticals, Inc. | 54,513.07 (Schedule G, line 133, page 13 of the filing PDF) | 10 |
| 134 | Apretude 600 mg/3 mL SUER49702026423Listed by the FDA as ApretudecabotegravirkitViiV Healthcare Company | 54,024.81 (Schedule G, line 134, page 14 of the filing PDF) | 24 |
| 135 | ublituximab (Briumvi) 450 mg in sodium chloride 0.9% 250 mL IVPB73150015006Listed by the FDA as Briumviublituximab150 mg/6 mLinjection, solution, concentrateTG Therapeutics, Inc. | 52,364.20 (Schedule G, line 135, page 14 of the filing PDF) | fewer than 6 (the count is not shown) |
| 136 | Enzalutamide00469012599Listed by the FDA as Xtandienzalutamide40 mgcapsuleAstellas Pharma US, Inc. | 46,125.59 (Schedule G, line 136, page 14 of the filing PDF) | fewer than 6 (the count is not shown) |
| 137 | omalizumab (Xolair) 300 mg/2 mL AtIn50242022755Listed by the FDA as Xolairomalizumab300 mg/2 mLinjection, solutionGenentech, Inc. | 51,498.38 (Schedule G, line 137, page 14 of the filing PDF) | 14 |
| 138 | romiPLOStim (Nplate) subcutaneous injection 125 mcg55513022301Listed by the FDA as Nplateromiplostim125 mcg/0.25 mLinjection, powder, lyophilized, for solutionAmgen, Inc | 45,660.63 (Schedule G, line 138, page 14 of the filing PDF) | 51 |
| 139 | immune globulin (human) (Privigen) 10% infusion 5 g44206043605Listed by the FDA as Privigenhuman immunoglobulin G5 g/50 mLliquidCSL Behring AG | 47,385.85 (Schedule G, line 139, page 14 of the filing PDF) | 190 |
| 140 | Zepbound 2.5 mg/0.5 mL x 4PEND AM00002250680Listed by the FDA as Zepboundtirzepatide2.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 45,660.63 (Schedule G, line 140, page 14 of the filing PDF) | 62 |
| 141 | Follistim AQ 900 units Cartridg78206013101Listed by the FDA as Follistim AQfollitropin900 IU/1.08 mLinjection, solutionOrganon LLC | 46,939.24 (Schedule G, line 141, page 14 of the filing PDF) | 152 |
| 142 | Aranesp (Albumin Free) 300 mcg/0.6 mL SOSY55513011101Listed by the FDA as Aranespdarbepoetin alfa300 mcg/0.6 mLinjection, solutionAmgen, Inc | 46,626.60 (Schedule G, line 142, page 14 of the filing PDF) | 89 |
| 143 | Skyrizi 150 mg/mL pen00074210001Listed by the FDA as Skyrizirisankizumab-rzaa150 mg/mLinjectionAbbVie Inc. | 74,123.45 (Schedule G, line 143, page 14 of the filing PDF) | fewer than 6 (the count is not shown) |
| 144 | tildrakizumab-asmn (Ilumya) syringe 100 mg47335017795Listed by the FDA as Ilumyatildrakizumab-asmn100 mg/mLinjection, solutionSun Pharmaceutical Industries, Inc. | 45,828.00 (Schedule G, line 144, page 14 of the filing PDF) | fewer than 6 (the count is not shown) |
| 145 | botulinum toxin Type A (Botox) 200 units SolR00023392102Listed by the FDA as BotoxonabotulinumtoxinA200 USP unitsinjection, powder, lyophilized, for solutionAllergan, Inc. | 39,454.32 (Schedule G, line 145, page 14 of the filing PDF) | 38 |
| 146 | luspatercept-aamt 25 mg PWDI59572071101Listed by the FDA as Reblozylluspatercept25 mginjection, powder, lyophilized, for solutionCelgene Corporation | 38,927.85 (Schedule G, line 146, page 14 of the filing PDF) | fewer than 6 (the count is not shown) |
| 147 | tremelimumab-actl 75 mg in sodium chloride 0.9% 50 mL chemo IVPB00310450525Listed by the FDA as Imjudotremelimumab25 mg/1.25 mLinjection, solutionAstraZeneca Pharmaceuticals LP | 44,317.86 (Schedule G, line 147, page 14 of the filing PDF) | fewer than 6 (the count is not shown) |
| 148 | reslizumab (Cinqair) 410 mg in sodium chloride 0.9% 50 mL IVPB59310061031Listed by the FDA as Cinqairreslizumab10 mg/mLinjection, solution, concentrateTeva Respiratory, LLC | 43,655.71 (Schedule G, line 148, page 14 of the filing PDF) | 14 |
| 149 | rituximab (Rituxan) 1,000 mg in sodium chloride 0.9% 1,000 mL IVPB (Patient Supplied)50242005306Listed by the FDA as Rituxanrituximab10 mg/mLinjection, solutionGenentech, Inc. | 43,417.02 (Schedule G, line 149, page 14 of the filing PDF) | 13 |
| 150 | adalimumab-bwwd (Hadlima,CF, PushTouch) 40 mg/0.4 mL AtIn78206018701Listed by the FDA as Hadlimaadalimumab-bwwd40 mg/0.4 mLsolutionOrganon LLC | 42,828.00 (Schedule G, line 150, page 14 of the filing PDF) | 59 |
| 151 | lecanemab irmb 200 mg/2 mL INJ62856021201Listed by the FDA as Leqembilecanemab100 mg/mLinjection, solutionEisai Inc. | 40,541.16 (Schedule G, line 151, page 14 of the filing PDF) | 93 |
| 152 | ustekinumab-stba (Steqeyma) 90 mg/mL Syrg72606002801Listed by the FDA as Steqeymaustekinumab-stba90 mg/mLinjection, solutionCELLTRION USA, Inc. | 40,155.98 (Schedule G, line 152, page 14 of the filing PDF) | 32 |
| 153 | polatuzumab vedotin 140 mg INJ50242010501Listed by the FDA as Polivypolatuzumab vedotin140 mg/7.52 mLinjection, powder, lyophilized, for solutionGenentech, Inc. | 40,101.00 (Schedule G, line 153, page 14 of the filing PDF) | fewer than 6 (the count is not shown) |
| 154 | durvalumab 120 mg/2.4 mL INJ00310450012Listed by the FDA as Imfinzidurvalumab120 mg/2.4 mLinjection, solutionAstraZeneca Pharmaceuticals LP | 38,506.22 (Schedule G, line 154, page 14 of the filing PDF) | 39 |
| 155 | guselkumab (Tremfya Pen) 200 mg/2 mL PnIj57894065102Listed by the FDA as Tremfyaguselkumab200 mg/2 mLinjectionJanssen Biotech, Inc. | 37,538.50 (Schedule G, line 155, page 14 of the filing PDF) | 8 |
| 156 | palbociclib (Ibrance) 75 mg Tab00069028403Listed by the FDA as Ibrancepalbociclib75 mgtablet, film coatedPfizer Laboratories Div Pfizer Inc | 75,157.25 (Schedule G, line 156, page 14 of the filing PDF) | fewer than 6 (the count is not shown) |
| 157 | Levonorgestrel (Liletta) 20.4 mcg/24 hr (8 yrs) 52 mg IUD 1 each00023585801Listed by the FDA as Lilettalevonorgestrel52 mgintrauterine deviceAllergan, Inc. | 35,350.00 (Schedule G, line 157, page 14 of the filing PDF) | 428 |
| 158 | Rinvoq ER 30 mg tablet00074231030Listed by the FDA as Rinvoqupadacitinib30 mgtablet, extended releaseAbbVie Inc. | 40,671.78 (Schedule G, line 158, page 14 of the filing PDF) | 16 |
| 159 | semaglutide, weight loss, (Wegovy) 1.7 mg/0.75 mL pen-injector00169451714Listed by the FDA as Wegovysemaglutide1.7 mg/0.75 mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 30,475.42 (Schedule G, line 159, page 14 of the filing PDF) | 55 |
| 160 | Ondansetron HCl 4 mg/2 mL SOLN00409475503Listed by the FDA as Ondansetron2 mg/mLinjection, solutionHospira, Inc. | 36,921.82 (Schedule G, line 160, page 14 of the filing PDF) | 30 |
| 161 | DOCEtaxeL (Taxotere) 130 mg in sodium chloride 0.9% 250 mL IVPB00409036601Listed by the FDA as Docetaxel20 mg/mLinjection, solutionHospira, Inc. | 36,653.92 (Schedule G, line 161, page 14 of the filing PDF) | fewer than 6 (the count is not shown) |
| 162 | Vemlidy tab 25 mg 3061958230101Listed by the FDA as Vemlidytenofovir alafenamide25 mgtabletGilead Sciences, Inc. | 47,667.53 (Schedule G, line 162, page 14 of the filing PDF) | 39 |
| 163 | immune globulin (Gamunex-C) 30 g13533080071Listed by the FDA as Gamunex-Cimmune globulin (human)10 g/100 mLinjectionGrifols USA, LLC | 34,055.84 (Schedule G, line 163, page 14 of the filing PDF) | 44 |
| 164 | Simponi inj 100 mg/mL57894007102Listed by the FDA as Simponigolimumab100 mg/mLinjection, solutionJanssen Biotech, Inc. | 31,587.68 (Schedule G, line 164, page 14 of the filing PDF) | 13 |
| 165 | ARIPiprazole (Abilify Maintena) 400 mg SERR59148024512Listed by the FDA as Abilify MaintenaaripiprazolekitOtsuka America Pharmaceutical, Inc. | 31,495.12 (Schedule G, line 165, page 14 of the filing PDF) | 22 |
| 166 | ixekizumab (Taltz Syringe) 80 mg/mL Syrg00002772411Listed by the FDA as Taltzixekizumab80 mg/mLinjection, solutionEli Lilly and Company | 28,130.00 (Schedule G, line 166, page 14 of the filing PDF) | fewer than 6 (the count is not shown) |
| 167 | tezepelumab-ekko (Tezspire) 210 mg/1.91 mL (110 mg/mL) PnIj55513012301Listed by the FDA as Tezspiretezepelumab-ekko210 mg/1.9 mLinjection, solutionAmgen Inc | 30,580.82 (Schedule G, line 167, page 14 of the filing PDF) | 8 |
| 168 | upadacitinib (Rinvoq) 45 mg Tb2400074104328Listed by the FDA as Rinvoqupadacitinib45 mgtablet, extended releaseAbbVie Inc. | 26,378.91 (Schedule G, line 168, page 14 of the filing PDF) | fewer than 6 (the count is not shown) |
| 169 | RabAvert PFS 1 IU 1 mL50632001001Listed by the FDA as RabAvertrabies vaccinekitBavarian Nordic A/S | 25,457.00 (Schedule G, line 169, page 14 of the filing PDF) | 100 |
| 170 | darunavir-cobi-emtri-tenof ala (Symtuza) 800-150-200-10 mg Tab59676080030Listed by the FDA as Symtuzadarunavir, cobicistat, emtricitabine, and tenofovir alafenamide800 mg; 150 mg; 200 mg; 10 mgtablet, film coatedJanssen Products LP | 29,520.30 (Schedule G, line 170, page 14 of the filing PDF) | 10 |
| 171 | cemiplimab-rwlc 350 mg in sodium chloride 0.9% 93 mL chemo IVPB61755000801Listed by the FDA as Libtayocemiplimab-rwlc50 mg/mLinjectionRegeneron Pharmaceuticals, Inc. | 29,233.50 (Schedule G, line 171, page 14 of the filing PDF) | 6 |
| 172 | dupilumab (Dupixent Syringe) 300 mg/2 mL Syrg00024591401Listed by the FDA as Dupixentdupilumab300 mg/2 mLinjection, solutionSanofi-Aventis U.S. LLC | 26,371.08 (Schedule G, line 172, page 15 of the filing PDF) | 9 |
| 173 | Kyleena 19.5 mg IUD50419042401Listed by the FDA as Kyleenalevonorgestrel19.5 mgintrauterine deviceBayer HealthCare Pharmaceuticals Inc. | 25,561.44 (Schedule G, line 173, page 15 of the filing PDF) | 42 |
| 174 | teriparatide 20 mcg/dose (620 mcg/2.48 mL) PnIj47781065289Listed by the FDA as Teriparatide250 mcg/mLinjection, solutionAlvogen, Inc. | 27,380.08 (Schedule G, line 174, page 15 of the filing PDF) | 22 |
| 175 | rucaparib (Rubraca) 300 mg Tab82154078501Listed by the FDA as Rubracarucaparib300 mgtablet, film coatedpharmaand GmbH | 26,992.50 (Schedule G, line 175, page 15 of the filing PDF) | fewer than 6 (the count is not shown) |
| 176 | Tibsovo 250 mg tab 6072694061760Listed by the FDA as Tibsovoivosidenib250 mgtablet, film coatedServier Pharmaceutical LLC | 24,360.19 (Schedule G, line 176, page 15 of the filing PDF) | fewer than 6 (the count is not shown) |
| 177 | riTUXimab-abbs (Truxima) 1,000 mg in sodium chloride 0.9% 1,000 mL IVPB63459010450Listed by the FDA as Truximarituximab-abbs10 mg/mLinjection, solutionCephalon, Inc. | 24,326.75 (Schedule G, line 177, page 15 of the filing PDF) | 10 |
| 178 | Tranexamic Acid 1,000 mg/10 mL SOLN55150018810Listed by the FDA as Tranexamic Acid100 mg/mLinjection, solutionEugia US LLC | 26,317.88 (Schedule G, line 178, page 15 of the filing PDF) | 224 |
| 179 | trametinib 2 mg Tab00078111215Listed by the FDA as Mekinisttrametinib2 mgtablet, film coatedNovartis Pharmaceuticals Corporation | 23,972.30 (Schedule G, line 179, page 15 of the filing PDF) | fewer than 6 (the count is not shown) |
| 180 | Trelstar Mixject 3.75 mg SUSR74676590201Listed by the FDA as Trelstartriptorelin pamoatekitVerity Pharmaceuticals Inc. | 25,030.80 (Schedule G, line 180, page 15 of the filing PDF) | 134 |
| 181 | ProvayBlue 50 mg/10 mL SOLN00517037405Listed by the FDA as Provaybluemethylene blue5 mg/mLinjectionAmerican Regent, Inc. | 21,644.13 (Schedule G, line 181, page 15 of the filing PDF) | 271 |
| 182 | Xifaxan tab 550 mg65649030302Listed by the FDA as Xifaxanrifaximin550 mgtabletSalix Pharmaceuticals, Inc. | 21,270.21 (Schedule G, line 182, page 15 of the filing PDF) | 11 |
| 183 | efgartigimod alfa-hyaluronidase qvfc 1,008 mg-11,200 units / 5.6 mL INJ73475310203Listed by the FDA as Vyvgart Hytruloefgartigimod alfa and hyaluronidase (human recombinant)180 mg/mL; 2,000 units/mLinjection, solutionargenx US | 24,285.80 (Schedule G, line 183, page 15 of the filing PDF) | fewer than 6 (the count is not shown) |
| 184 | Stelara PFS 45 mg/0.5 mL 157894006003Listed by the FDA as Stelaraustekinumab45 mg/0.5 mLinjection, solutionJanssen Biotech, Inc. | 20,868.75 (Schedule G, line 184, page 15 of the filing PDF) | fewer than 6 (the count is not shown) |
| 185 | guselkumab (Tremfya) 100 mg/mL AtIn57894064011Listed by the FDA as Tremfyaguselkumab100 mg/mLinjectionJanssen Biotech, Inc. | 23,517.01 (Schedule G, line 185, page 15 of the filing PDF) | 6 |
| 186 | lenvatinib (Lenvima) 4 mg cap62856070430Listed by the FDA as Lenvimalenvatinib4 mgcapsuleEisai Inc. | 22,046.42 (Schedule G, line 186, page 15 of the filing PDF) | fewer than 6 (the count is not shown) |
| 187 | Acetaminophen 10 mg/mL SOLN63323043400Listed by the FDA as Acetaminophen10 mg/mLinjectionFresenius Kabi USA, LLC | 21,811.11 (Schedule G, line 187, page 15 of the filing PDF) | 6,566 |
| 188 | semaglutide, weight loss, (Wegovy) 0.5 mg/0.5 mL pen-injector00169450514Listed by the FDA as Wegovysemaglutide0.5 mg/0.5 mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 18,092.04 (Schedule G, line 188, page 15 of the filing PDF) | 31 |
| 189 | Fasenra 30 mg PFS00310173030Listed by the FDA as Fasenrabenralizumab30 mg/mLinjection, solutionAstraZeneca Pharmaceuticals LP | 17,844.34 (Schedule G, line 189, page 15 of the filing PDF) | fewer than 6 (the count is not shown) |
| 190 | nivolumab-hyaluronidase-nvhy 600 mg-10,000 units/5 mL Soln 600 mg00003612001Listed by the FDA as Opdivo Qvantignivolumab and hyaluronidase-nvhy120 mg/mL; 2,000 units/mLinjection, solutionE.R. Squibb & Sons, L.L.C. | 16,668.96 (Schedule G, line 190, page 15 of the filing PDF) | fewer than 6 (the count is not shown) |
| 191 | Indocyanine Green 25 mg SOLR70100042402Listed by the FDA as Indocyanine Greenindocyanine green and waterkitRenew Pharmaceuticals Limited | 20,599.42 (Schedule G, line 191, page 15 of the filing PDF) | 186 |
| 192 | pegfilgrastim (Neulasta) injection 6 mg55513019001Listed by the FDA as Neulastapegfilgrastim6 mg/0.6 mLinjectionAmgen, Inc | 20,592.39 (Schedule G, line 192, page 15 of the filing PDF) | 63 |
| 193 | belimumab (Benlysta) 750 mg in sodium chloride 0.9% 250 mL IVPB49401010201Listed by the FDA as Benlystabelimumab400 mg/5 mLinjection, powder, lyophilized, for solutionGlaxoSmithKline LLC | 20,302.67 (Schedule G, line 193, page 15 of the filing PDF) | fewer than 6 (the count is not shown) |
| 194 | trametinib (Mekinist) 0.5 mg Tab00078110515Listed by the FDA as Mekinisttrametinib0.5 mgtablet, film coatedNovartis Pharmaceuticals Corporation | 20,096.64 (Schedule G, line 194, page 15 of the filing PDF) | fewer than 6 (the count is not shown) |
| 195 | dulaglutide (Trulicity) 4.5 mg/0.5 mL PnIj00002318280Listed by the FDA as Trulicitydulaglutide4.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 15,629.58 (Schedule G, line 195, page 15 of the filing PDF) | 19 |
| 196 | Wegovy inj 1 mg00169450114Listed by the FDA as Wegovysemaglutide1 mg/0.5 mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 20,549.08 (Schedule G, line 196, page 15 of the filing PDF) | 37 |
| 197 | F/S Sodium Chloride 0.9% 250 mL00338004902Listed by the FDA as Sodium Chloride9 g/1,000 mLinjection, solutionBaxter Healthcare Corporation | 17,112.09 (Schedule G, line 197, page 15 of the filing PDF) | 2,631 |
| 198 | ustekinumab 130 mg/26 mL VIAL57894005427Listed by the FDA as Stelaraustekinumab130 mg/26 mLsolutionJanssen Biotech, Inc. | 16,826.46 (Schedule G, line 198, page 15 of the filing PDF) | 7 |
| 199 | PACLItaxel 300 mg/50 mL MDV61703034250Listed by the FDA as Paclitaxel6 mg/mLinjection, solutionHospira, Inc. | 16,774.57 (Schedule G, line 199, page 15 of the filing PDF) | 1,960 |
| 200 | leuprolide (3-month) (Lupron Depot) injection 22.5 mg00074334603Listed by the FDA as Lupron Depotleuprolide acetatekitAbbVie Inc. | 13,980.26 (Schedule G, line 200, page 15 of the filing PDF) | 69 |
| 201 | leuprolide (1-month) (Lupron Depot) injection 7.5 mg00074364203Listed by the FDA as Lupron Depotleuprolide acetatekitAbbVie Inc. | 16,359.81 (Schedule G, line 201, page 15 of the filing PDF) | 179 |
| 202 | Gemtesa tab 75 mg73336007530Listed by the FDA as Gemtesavibegron75 mgtablet, film coatedSumitomo Pharma America, Inc. | 29,106.76 (Schedule G, line 202, page 15 of the filing PDF) | 110 |
| 203 | follitropin alfa (Gonal-F RFF Redi-Ject) 900/1.5 units/mL PnIj44087111701Listed by the FDA as Gonal-f RFF Redi-jectfollitropin900 IU/1.5 mLinjection, solutionEMD Serono, Inc. | 15,794.98 (Schedule G, line 203, page 15 of the filing PDF) | 42 |
| 204 | dulaglutide (Trulicity) 3 mg/0.5 mL PnIj00002223680Listed by the FDA as Trulicitydulaglutide3 mg/0.5 mLinjection, solutionEli Lilly and Company | 13,332.46 (Schedule G, line 204, page 15 of the filing PDF) | 18 |
| 205 | Ativan 2 mg/mL SOLN00641600125Listed by the FDA as Ativanlorazepam2 mg/mLinjectionHikma Pharmaceuticals USA Inc. | 15,227.04 (Schedule G, line 205, page 15 of the filing PDF) | 137 |
| 206 | betamethasone acet,sod phos (Celestone) injection 12 mg78206011801Listed by the FDA as Celestone Soluspanbetamethasone acetate and betamethasone sodium phosphate3 mg/mL; 3 mg/mLinjection, suspensionOrganon LLC | 15,174.72 (Schedule G, line 206, page 15 of the filing PDF) | 418 |
| 207 | immune globulin (human) (Gammagard Liquid) 10% infusion 100 g (Patient Supplied)00944270005Listed by the FDA as Gammagard Liquidimmune globulin infusion (human)100 mg/mLinjection, solutionTakeda Pharmaceuticals America, Inc. | 15,077.02 (Schedule G, line 207, page 15 of the filing PDF) | 38 |
| 208 | Lenvima 20 mg BPK cap 6062856072030Listed by the FDA as Lenvimalenvatinib10 mgcapsuleEisai Inc. | 12,801.91 (Schedule G, line 208, page 15 of the filing PDF) | fewer than 6 (the count is not shown) |
| 209 | cetuximab (Erbitux) IVPB 250 mg/m2 = 500 mg 250 mL66733094823Listed by the FDA as Erbituxcetuximab2 mg/mLsolutionImClone LLC | 14,754.70 (Schedule G, line 209, page 15 of the filing PDF) | 38 |
| 210 | Wegovy 0.25 mg 4 pref pens00169452514Listed by the FDA as Wegovysemaglutide0.25 mg/0.5 mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 12,795.24 (Schedule G, line 210, page 16 of the filing PDF) | 26 |
| 211 | cycloPHOSphamide 1 g SOLR10019095601Listed by the FDA as Cyclophosphamide1 g/50 mLinjection, powder, for solutionBaxter Healthcare Company | 13,565.43 (Schedule G, line 211, page 16 of the filing PDF) | 341 |
| 212 | adalimumab-ryvk (Simlandi,CF, Autoinjector) 40 mg/0.4 mL atIK51759040202Listed by the FDA as Simlandiadalimumab-ryvkkitTeva Pharmaceuticals USA, Inc. | 13,377.00 (Schedule G, line 212, page 16 of the filing PDF) | 19 |
| 213 | epoetin alfa-epbx (Retacrit) 40,000 units/mL Soln00069130904Listed by the FDA as Retacritepoetin alfa-epbx40,000 IU/mLinjection, solutionPfizer Laboratories Div Pfizer Inc | 12,712.42 (Schedule G, line 213, page 16 of the filing PDF) | 83 |
| 214 | adalimumab-adaz 40 mg/0.4 mL PnIj61314032720Listed by the FDA as Adalimumabadalimumab-adaz40 mg/0.4 mLinjection, solutionSandoz Inc | 13,087.50 (Schedule G, line 214, page 16 of the filing PDF) | 24 |
| 215 | darbepoetin alfa 500 mcg/1 mL syringe55513003201Listed by the FDA as Aranespdarbepoetin alfa500 mcg/mLinjection, solutionAmgen, Inc | 13,087.02 (Schedule G, line 215, page 16 of the filing PDF) | 11 |
| 216 | ganirelix 250 mcg/0.5 mL Syrg00548500100Listed by the FDA as Ganirelix Acetate250 mcg/0.5 mLinjectionAmphastar Pharmaceuticals, Inc. | 12,554.61 (Schedule G, line 216, page 16 of the filing PDF) | 115 |
| 217 | inFLIXimab-abda (Renflexis) 100 mg/10 mL PWDI78206016201Listed by the FDA as Renflexisinfliximab100 mginjection, powder, lyophilized, for solutionOrganon LLC | 12,301.90 (Schedule G, line 217, page 16 of the filing PDF) | 12 |
| 218 | Dupixent inj 200 mg/1.14 mL 200024591902Listed by the FDA as Dupixentdupilumab200 mg/1.14 mLinjection, solutionSanofi-Aventis U.S. LLC | 11,726.76 (Schedule G, line 218, page 16 of the filing PDF) | fewer than 6 (the count is not shown) |
| 219 | insulin degludec 200 units/mL (3 mL) InPn00169255013Listed by the FDA as Tresibainsulin degludec200 units/mLinjection, solutionNovo Nordisk | 11,250.06 (Schedule G, line 219, page 16 of the filing PDF) | 17 |
| 220 | Diprivan 200 mg/20 mL EMUL63323026929Listed by the FDA as Diprivanpropofol10 mg/mLinjection, emulsionFresenius Kabi USA, LLC | 12,379.11 (Schedule G, line 220, page 16 of the filing PDF) | 11,870 |
| 221 | tocilizumab (Actemra) 160 mg in sodium chloride 0.9% 100 mL IVPB50242013501Listed by the FDA as Actemratocilizumab80 mg/4 mLinjection, solution, concentrateGenentech, Inc. | 12,336.52 (Schedule G, line 221, page 16 of the filing PDF) | 32 |
| 222 | Insulin Glargine,HUM.REC.Anlog00002771559Listed by the FDA as Basaglar KwikPeninsulin glargine100 IU/mLinjection, solutionEli Lilly and Company | 15,438.80 (Schedule G, line 222, page 16 of the filing PDF) | 45 |
| 223 | benralizumab (Fasenra) subQ syringe 30 mg (Patient Supplied)00310183030Listed by the FDA as Fasenrabenralizumab30 mg/mLinjection, solutionAstraZeneca Pharmaceuticals LP | 11,386.09 (Schedule G, line 223, page 16 of the filing PDF) | 17 |
| 224 | everolimus, antineoplastic, 5 mg Tab70377001123Listed by the FDA as Everolimus5 mgtabletBiocon Pharma Inc. | 11,170.62 (Schedule G, line 224, page 16 of the filing PDF) | fewer than 6 (the count is not shown) |
| 225 | eptinezumab (Vyepti) 100 mg, sodium chloride 0.9%67386013051Listed by the FDA as Vyeptieptinezumab-jjmr100 mg/mLinjectionLundbeck Pharmaceuticals LLC | 11,068.19 (Schedule G, line 225, page 16 of the filing PDF) | 7 |
| 226 | obinutuzumab 1,000 mg/40 mL SOLN MDV50242007001Listed by the FDA as Gazyvaobinutuzumab1,000 mg/40 mLinjection, solution, concentrateGenentech, Inc. | 10,567.22 (Schedule G, line 226, page 16 of the filing PDF) | fewer than 6 (the count is not shown) |
| 227 | zoledronic acid (Reclast) IVPB 5 mg25021083082Listed by the FDA as Zoledronic Acid0.05 mg/mLinjection, solutionSagent Pharmaceuticals | 10,522.84 (Schedule G, line 227, page 16 of the filing PDF) | 95 |
| 228 | acarbose (Precose) 25 mg tablet00054014025Listed by the FDA as Acarbose25 mgtabletHikma Pharmaceuticals USA Inc. | 10,416.25 (Schedule G, line 228, page 16 of the filing PDF) | fewer than 6 (the count is not shown) |
| 229 | Descovy tab 200/25 mg61958200201Listed by the FDA as Descovyemtricitabine and tenofovir alafenamide200 mg; 25 mgtabletGilead Sciences, Inc. | 17,115.06 (Schedule G, line 229, page 16 of the filing PDF) | 19 |
| 230 | triptorelin (Trelstar Mixject) intramuscular injection 11.25 mg74676590401Listed by the FDA as Trelstartriptorelin pamoatekitVerity Pharmaceuticals Inc. | 10,049.29 (Schedule G, line 230, page 16 of the filing PDF) | 6 |
| 231 | DOXOrubicin HCl Liposomal 2 mg/mL SUSP70710153101Listed by the FDA as Doxorubicin Hydrochloride2 mg/mLinjectable, liposomalZydus Pharmaceuticals USA Inc. | 10,027.47 (Schedule G, line 231, page 16 of the filing PDF) | 94 |
| 232 | CARBOplatin 600 mg/60 mL SOLN55150038601Listed by the FDA as Carboplatin600 mg/60 mLinjection, solutionEugia US LLC | 9,888.06 (Schedule G, line 232, page 16 of the filing PDF) | 142 |
| 233 | spironolactone (Aldactone) 100 mg tablet53746051501Listed by the FDA as Spironolactone100 mgtabletAmneal Pharmaceuticals of New York LLC | 9,710.18 (Schedule G, line 233, page 16 of the filing PDF) | fewer than 6 (the count is not shown) |
| 234 | insulin glargine U-300 conc 300 units/mL (3 mL) InPn00024587102Listed by the FDA as Toujeo Maxinsulin glargine300 units/mLinjection, solutionSanofi-Aventis U.S. LLC | 9,658.42 (Schedule G, line 234, page 16 of the filing PDF) | 44 |
| 235 | alteplase (Activase) injection 2 mg50242004164Listed by the FDA as Cathflo Activasealteplase2.2 mg/2 mLinjection, powder, lyophilized, for solutionGenentech, Inc. | 9,570.54 (Schedule G, line 235, page 16 of the filing PDF) | 180 |
| 236 | cephalexin (Kefelx) 125 mg/5 mL suspension68180044001Listed by the FDA as Cephalexin125 mg/5 mLfor suspensionLupin Pharmaceuticals, Inc. | 9,475.89 (Schedule G, line 236, page 16 of the filing PDF) | fewer than 6 (the count is not shown) |
| 237 | norethindrone (Micronor) 0.35 mg tablet68462030529Listed by the FDA as Norethindrone0.35 mgtabletGlenmark Pharmaceuticals Inc., USA | 9,254.88 (Schedule G, line 237, page 16 of the filing PDF) | fewer than 6 (the count is not shown) |
| 238 | denosumab-bbdz (Jubbonti) injection 60 mg61314024063Listed by the FDA as Jubbontidenosumab60 mg/mLinjectionSandoz Inc | 9,192.15 (Schedule G, line 238, page 16 of the filing PDF) | 6 |
| 239 | netupitant-palonosetron (Akynzeo, netupitant,) 300-0.5 mg cap69639010101Listed by the FDA as Akynzeonetupitant and palonosetron300 mg; 0.5 mgcapsuleHelsinn Therapeutics (U.S.), Inc. | 9,161.12 (Schedule G, line 239, page 16 of the filing PDF) | fewer than 6 (the count is not shown) |
| 240 | riTUXimab-pvvr (Ruxience) 100 mg/10 mL INJ00069023801Listed by the FDA as Ruxiencerituximab-pvvr100 mg/10 mLinjection, solutionPfizer Laboratories Div Pfizer Inc | 9,145.21 (Schedule G, line 240, page 16 of the filing PDF) | 46 |
| 241 | sofosbuvir-velpatasvir 400-100 mg Tab72626270101Listed by the FDA as Sofosbuvir and Velpatasvirvelpatasvir and sofosbuvir100 mg; 400 mgtablet, film coatedAsegua Therapeutics LLC | 9,084.10 (Schedule G, line 241, page 16 of the filing PDF) | fewer than 6 (the count is not shown) |
| 242 | tocilizumab-aazg 162 mg/0.9 mL PnIj65219058401Listed by the FDA as Tyennetocilizumab-aazg162 mg/0.9 mLinjection, solutionFresenius Kabi USA, LLC | 9,040.38 (Schedule G, line 242, page 16 of the filing PDF) | 8 |
| 243 | naltrexone ER (VivitroL) 380 mg SERR65757030001Listed by the FDA as VivitrolnaltrexonekitAlkermes, Inc. | 8,959.47 (Schedule G, line 243, page 16 of the filing PDF) | 15 |
| 244 | cycloPHOSphamide 500 mg PWDI10019095501Listed by the FDA as Cyclophosphamide500 mg/25 mLinjection, powder, for solutionBaxter Healthcare Company | 8,843.05 (Schedule G, line 244, page 16 of the filing PDF) | 224 |
| 245 | paliperidone palmitate ER (Invega Sustenna) 234 mg/1.5 mL Syrg50458056401Listed by the FDA as Invega Sustennapaliperidone palmitate234 mg/1.5 mLinjectionJanssen Pharmaceuticals, Inc. | 7,905.18 (Schedule G, line 245, page 16 of the filing PDF) | fewer than 6 (the count is not shown) |
| 246 | fezolinetant 45 mg Tab00469266030Listed by the FDA as Veozahfezolinetant45 mgtablet, film coatedAstellas Pharma US, Inc. | 18,368.69 (Schedule G, line 246, page 16 of the filing PDF) | 35 |
| 247 | fosaprepitant (Emend) 150 mg in sodium chloride 250 mL IVPB16714024801Listed by the FDA as Fosaprepitantfosaprepitant dimeglumine150 mg/5 mLinjection, powder, lyophilized, for solutionNorthStar RxLLC | 7,358.66 (Schedule G, line 247, page 16 of the filing PDF) | 209 |
| 248 | PACLitaxel (Taxol) 102 mg in sodium chloride 0.9% 250 mL IVPB63323076350Listed by the FDA as Paclitaxel6 mg/mLinjection, solutionFresenius Kabi USA, LLC | 7,357.15 (Schedule G, line 248, page 17 of the filing PDF) | 133 |
| 249 | dulaglutide (Trulicity) 0.75 mg/0.5 mL PnIj00002143380Listed by the FDA as Trulicitydulaglutide0.75 mg/0.5 mLinjection, solutionEli Lilly and Company | 7,150.44 (Schedule G, line 249, page 17 of the filing PDF) | 10 |
| 250 | aripiprazole (Abilify) 15 mg tablet13668021930Listed by the FDA as Aripiprazole15 mgtabletTorrent Pharmaceuticals Limited | 7,064.24 (Schedule G, line 250, page 17 of the filing PDF) | fewer than 6 (the count is not shown) |
| 251 | iodine 5%-10% topical 14 mL SOLN48433023015Listed by the FDA as Strong Iodine Solution700 mg/mL; 1,400 mg/mLsolution/ dropsSafecor Health, LLC | 6,928.69 (Schedule G, line 251, page 17 of the filing PDF) | 239 |
| 252 | DOXOrubicin liposome (Doxil) 60 mg in dextrose 5% 250 mL IVPB70710153001Listed by the FDA as Doxorubicin Hydrochloride2 mg/mLinjectable, liposomalZydus Pharmaceuticals USA Inc. | 6,906.40 (Schedule G, line 252, page 17 of the filing PDF) | 6 |
| 253 | Rocuronium Bromide 50 mg/5 mL SOLN00409318910Listed by the FDA as Rocuronium Bromide10 mg/mLinjection, solutionHospira, Inc. | 6,900.63 (Schedule G, line 253, page 17 of the filing PDF) | 3,798 |
| 254 | medroxyPROGESTERone Acetate 150 mg/mL SUSY66993037179Listed by the FDA as Medroxyprogesterone Acetate150 mg/mLinjection, suspensionPrasco Laboratories | 6,730.84 (Schedule G, line 254, page 17 of the filing PDF) | 771 |
| 255 | ceFAZolin Sodium 2 g SOLR00143913925Listed by the FDA as Cefazolin2 ginjection, powder, for solutionHikma Pharmaceuticals USA Inc. | 6,710.77 (Schedule G, line 255, page 17 of the filing PDF) | 2,651 |
| 256 | dolutegravir (Tivicay) 50 mg tablet49702022813Listed by the FDA as Tivicaydolutegravir sodium50 mgtablet, film coatedViiV Healthcare Company | 16,130.39 (Schedule G, line 256, page 17 of the filing PDF) | fewer than 6 (the count is not shown) |
| 257 | Tresiba Flex inj 100 units00169266015Listed by the FDA as Tresibainsulin degludec100 units/mLinjection, solutionNovo Nordisk | 6,577.23 (Schedule G, line 257, page 17 of the filing PDF) | 14 |
| 258 | Doxycycline Hyclate 100 mg SOLR16714064410 | 6,527.82 (Schedule G, line 258, page 17 of the filing PDF) | 374 |
| 259 | risperiDONE microspheres ER (RisperDAL Consta) injection suspension50458030811Listed by the FDA as Risperdal ConstarisperidonekitJanssen Pharmaceuticals, Inc. | 6,315.12 (Schedule G, line 259, page 17 of the filing PDF) | 15 |
| 260 | eluxadoline (Viberzi) 75 mg Tab61874007560Listed by the FDA as Viberzieluxadoline75 mgtablet, film coatedAllergan, Inc. | 6,255.12 (Schedule G, line 260, page 17 of the filing PDF) | 12 |
| 261 | Invega Sustenna 117 mg/0.75 mL Syrg50458056201Listed by the FDA as Invega Sustennapaliperidone palmitate117 mg/0.75 mLinjectionJanssen Pharmaceuticals, Inc. | 6,162.82 (Schedule G, line 261, page 17 of the filing PDF) | 10 |
| 262 | deucravacitinib (Sotyktu) 6 mg Tab00003089511Listed by the FDA as Sotyktudeucravacitinib6 mgtablet, film coatedE.R. Squibb & Sons, L.L.C. | 5,950.89 (Schedule G, line 262, page 17 of the filing PDF) | fewer than 6 (the count is not shown) |
| 263 | fentaNYL (Duragesic) 100 mcg/hr00378912498Listed by the FDA as Fentanyl100 mcg/hourpatchMylan Pharmaceuticals Inc. | 5,887.96 (Schedule G, line 263, page 17 of the filing PDF) | fewer than 6 (the count is not shown) |
| 264 | prucalopride 2 mg Tab54092054701Listed by the FDA as Motegrityprucalopride2 mgtablet, film coatedTakeda Pharmaceuticals America, Inc. | 5,875.00 (Schedule G, line 264, page 17 of the filing PDF) | 11 |
| 265 | beclomethasone HFA (Qvar) 40 mcg/actuation HFAB59310030240Listed by the FDA as Qvar Redihalerbeclomethasone dipropionate HFA40 mcgaerosol, meteredTeva Respiratory, LLC | 5,799.99 (Schedule G, line 265, page 17 of the filing PDF) | fewer than 6 (the count is not shown) |
| 266 | Emerphed 5 mg/mL SOLN14789025010Listed by the FDA as Emerphedephedrine sulfate5 mg/mLinjectionNexus Pharamaceuticals Inc. | 5,504.20 (Schedule G, line 266, page 17 of the filing PDF) | 998 |
| 267 | Vancomycin HCl 1.25 g SOLR67457082399Listed by the FDA as Vancomycin Hydrochloride1.25 g/25 mLinjection, powder, lyophilized, for solutionMylan Institutional LLC | 5,483.22 (Schedule G, line 267, page 17 of the filing PDF) | 20 |
| 268 | DOCEtaxeL (Taxotere) 104 mg in sodium chloride 0.9% 250 mL IVPB25021024504Listed by the FDA as Docetaxeldocetaxel anhydrous20 mg/mLinjection, solutionSagent Pharmaceuticals | 5,270.58 (Schedule G, line 268, page 17 of the filing PDF) | 30 |
| 269 | Glydo 2% PRSY25021067376Listed by the FDA as Glydolidocaine hydrochloride20 mg/mLjellySagent Pharmaceuticals | 5,163.61 (Schedule G, line 269, page 17 of the filing PDF) | 1,939 |
| 270 | Tymlos SY 2 mg/mL 1.56 mL 30DS SPD70539000102Listed by the FDA as Tymlosabaloparatide3.12 mg/1.56 mLinjection, solutionRadius Health, Inc. | 36,171.62 (Schedule G, line 270, page 17 of the filing PDF) | 49 |
| 271 | menotropins (Menopur) 75 units SolR55566750102Listed by the FDA as MenopurmenotropinskitFerring Pharmaceuticals Inc. | 21,826.75 (Schedule G, line 271, page 17 of the filing PDF) | 347 |
| 272 | Crinone GL 8% 15x1.125 g PFA VAG00023615108Listed by the FDA as Crinoneprogesterone90 mg/1.125 ggelAllergan, Inc. | 13,072.44 (Schedule G, line 272, page 17 of the filing PDF) | 48 |
| 273 | Mirabegron 50 mg ER tablets68180015206Listed by the FDA as Mirabegron50 mgtablet, film coated, extended releaseLupin Pharmaceuticals, Inc. | 11,169.84 (Schedule G, line 273, page 17 of the filing PDF) | 36 |
| 274 | Gemtesa tab 75 mg73336007590Listed by the FDA as Gemtesavibegron75 mgtablet, film coatedSumitomo Pharma America, Inc. | 5,040.96 (Schedule G, line 274, page 17 of the filing PDF) | 13 |
No row matches. | |||
| Total Prescription Drugs individually under $5,000 | 623,385.98 (Schedule G, row for amounts under $5,000, page 17 of the filing PDF) | 206,566 (Schedule G, claims on the row for amounts under $5,000, page 17 of the filing PDF) | |
| Total Costs of Prescription Drugs Obtained Through 340B Program Claimed for Reimbursement | 55,496,300.74 (Schedule G, printed total, page 17 of the filing PDF) | 268,715 (Schedule G, printed claims total, page 17 of the filing PDF) | |
The rows at the foot of the table are always shown. The sum above does not include them.
What “fewer than 6” means. A count of 1 to 5 is not shown on this site or in its data files. Methods, section 9, says how.
Amounts and counts are the filer’s own, in US dollars. They are written here with commas between thousands, and an amount filed with one decimal place is written with two. No value is changed: the filing and the download keep each figure as typed.
Drug names are the filer’s own words. Filers type them in many ways, so this page writes them one way: capitals, spaces, unit names such as mg and mL, a zero before a decimal point, and commas in long numbers. No word is changed, spelled out or left out, and shorthand stays as the filer typed it. The filing and the download keep each name as typed, and a search here reads both.
“Listed by the FDA as” is not part of the filing. It is the name, ingredient, strength, form and labeler that the U.S. Food and Drug Administration’s National Drug Code Directory lists for the row’s code, as downloaded on 11 November 2026. 273 of the 274 rows have one. A row has none when its code is not filed as one 11-digit code or the directory has never listed it. Where the directory has since dropped a code, the name is kept as it was last listed, and the line says so. The directory’s capitals, strengths and unit names are written one way on this page. How a code is matched
Source
- Filing PDF
- Open Schedule G on the State of Rhode Island's website
- SHA-256
- 9faf818e60eb8284255d9bb1d86d5ae1ad548be76edaffda4c8f9d28dc42c917
- Retrieved
- 11 November 2026
- Pages used
- 10 to 17 of 19